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INTRODUCTION
Methotrexate  is  an  anti-metabolite  widely  used  in  malignancy,  rheumatoid 
arthritis and refractory cases of psoriasis1. The value of low dose methotrexate is well 
established2-4. Most patients are able to tolerate low dose methotrexate with generally 
sustained  efficacy5.  The  main  pulmonary  side  effect  of  methotrexate  is  interstitial 
pneumonitis.  Its  incidence has been found to be about 7 to 8%, in studies in which 
methotrexate  at  antineoplastic  doses  was  used,  in  combination  with  other  cytotoxic 
agents6. There are evidences of pulmonary function defects in patients on long term low 
dose  methotrexate  in  rheumatoid  arthritis  patients.  Acute  methotrexate  induced 
pneumonitis has also been reported after low-dose therapy (<20 mg/wk) for rheumatoid 
arthritis7-12.  Pulmonary  function  test  of  methotrexate  pneumonitis  patients  show 
restrictive  pattern  with  impairment  in  diffusion  capacity  of  carbon  monoxide.  It  is 
known that in patients receiving other cytotoxic drugs such as bleomycin, abnormalities 
in pulmonary function can be detected before the patients become symptomatic13,15. 
           Because methotrexate is frequently used in patients suffering from conditions 
such as RA, dermatomyositis or sarcoidosis, which can be associated with interstitial 
lung  disease,  determining  the  exact  role  of  methotrexate  in  the  development  of 
pulmonary complications in these 
patients seems to be difficult. Therefore, we conducted a cross-sectional study to analyse 
the findings found on chest x-rays, high resolution computed tomography (HRCT) and 
pulmonary  function  tests  (PFT)  in  a  cohort  of  patients  without  previous  recognized 
interstitial  lung  disease  who  were  taking  methotrexate  as  a  treatment  for  psoriatic 
arthritis, a condition not associated with pleuropulmonary disease16.
AIM OF THE STUDY
To know the incidence of pulmonary toxicity and derangements in pulmonary 
function in psoriasis  patients taking Methotrexate on long term basis  through DLco, 
spirometry and radiological evaluation.
REVIEW OF LITERATURE
PSORIASIS:
Psoriasis  is  a  non-infectious,  chronic  inflammatory  disease  of  the  skin, 
characterised  by  well-defined  erythematous  plaques  with  silvery  scales,  with  a 
predilection for the extensor surfaces and scalp, and a chronic fluctuating course. The 
prevalence is approximately 2% in European  populations. Accurate figures for many 
other parts of the world are not available but there seems to be consistent evidence that 
the prevalence of psoriasis is lower in people of African origin and lower still in some 
Asian communities such as the Japanese. Psoriasis may start at any age but is unusual 
before the age of 5; the oldest recorded onset was in a patient aged 107. There appear to 
be two epidemiological patterns of psoriasis: The first shows an onset in the teenage and 
early adult years; an increased prevalence of HLA Cw6. In a second grouping, disease 
onset is in the fifties or sixties, a family history is less common and the HLA group Cw6 
is not so prominent. Some authors refer to these two groups of patients as type 1 and 
type 2 psoriatics.  The clinical course of psoriasis is very variable. As a general rule 
clinical impressions suggest that the earlier the age of onset and the more severe the 
initial presentation, the more severe the lifetime course of the disease.
Aetiology  :There  are  two  key  pathophysiological  aspects  to  the  abnormalities  in 
psoriatic  plaques:  First,  the  keratinocytes  hyperproliferate  with  a  grossly  increased 
mitotic index and an abnormal pattern of differentiation involving the retention of nuclei 
in the stratum corneum (in normal skin the dead stratum corneum cells do not have 
nuclei). Second, there is a large inflammatory cell infiltrate comprising polymorphs, 
T cells and other inflammatory cells.  It is uncertain which of these characteristics is 
primary. Traditionally, psoriasis was viewed primarily as a disorder of cell turnover but 
in  recent  years  there  has  been  increased  support  for  the  hypothesis  that  the 
hyperproliferation may be secondary to the inflammatory infiltrate and that the increase 
in  keratinocyte  proliferation  is  a  consequence  of  inflammatory  cell  mediators  or 
signalling.There is a large familial component to psoriasis. Formal estimates from twin 
studies suggest a hereditability of around 80%. In monozygotic twins perhaps one-third 
of pairs will be concordant for psoriasis. Put another way, two-thirds of monozygotic 
twins will not be concordant despite an apparently identical or near-identical genetic 
background. The mode of inheritance of psoriasis does not fit a clear Mendelian pattern 
and,  like  atopic  dermatitis,  is  therefore  described as  genetically  complex.  Empirical 
estimates  suggest  that  if  one  parent  has  psoriasis,  then  the  chance  of  a  child  being 
affected is in the order of 15-20%. If both parents have psoriasis, the probability of a 
child being affected is 0.5. Both these estimates are increased if one sibling already has 
the disease. Genome scanning linkage and association studies have indicated various 
chromosomal  areas  of  susceptibility  including  the  HLA  region.  Disordered  cell 
proliferation in psoriasis is reflected by the increase in the number of mitoses visible in 
the psoriatic plaque. The transit time-that is, the time it takes for keratinocytes in the 
basal layer to leave the epidermis-is shortened in psoriasis from perhaps 28 to 5 days. 
Whilst it used to be thought that the cell cycle was actually reduced in psoriasis, more 
recent data suggest that it is just that the proportion of cycling cells (rather than cells that 
are in G0) is increased.
There are some data suggesting that the non-plaque skin also shows an elevated 
rate of proliferation, although any increase above background rate is modest. These data 
have not been confirmed in all studies. The nails of patients with psoriasis, even when 
clinically  unaffected,  do,  however,  grow  more  quickly  than  those  of  controls.  The 
importance  of  keratinocyte  hyperproliferation  initially  received  support  from  the 
demonstration  that  cytostatic  drugs  such  as  methotrexate  were  clinically  useful. 
However, more recent data suggest that methotrexate 
may exert its effects primarily through an influence on the immune system.
The evidence implicating a key role for an immune pathogenesis relates to: 
The association with certain HLA groups (HLA Cw6) 
The success of certain immunosuppressive drugs (such as ciclosporin) in improving the 
clinical state of  the disease 
Reports of the development of psoriasis in recipients of bone marrow transplants from 
donors with a history of psoriasis.
The precise molecular mechanisms operating in psoriasis are, however, poorly 
understood. A large number of theories have been advanced over the last 30 or 40 years 
claiming that one particular mediator may be a key or rate-limiting factor in psoriasis. 
The majority of these explanations have not stood the test of time, nor have they 
provided useful therapeutic insight. 
Psoriasis  is  a  chronic  disease  characterised  by  variation  in  both  temporal  and 
spatial extent. Most of this variation cannot be explained. At any one time perhaps 10% 
of people who have received the diagnosis of psoriasis have no lesions and perhaps 15% 
may report remissions of up to 5 years or more.
m
METHOTREXATE
Methotrexate is a folate antagonist used as a chemotherapeutic agent as well as in the 
treatment of non-neoplastic inflammatory diseases.  When used in high doses for  the 
treatment  of  cancers,  the incidence  of  pulmonary  toxicity  is  estimated  at  7  percent. 
Toxicity does not appear to have dose dependency but may be related to frequency of 
administration. In one study, daily or weekly treatment carried more risk of pulmonary 
injury than treatment every 2 to 4 weeks. Synergistic toxicity has been reported with 
combination  therapy  using  cyclophosphamide.  Tapering  of  corticosteroid  therapy  or 
adrenalectomy  may  also  increase  the  risk  of  Methotrexate  induced  toxicity17.  The 
mechanism  of  methotrexate-induced  lung  injury  is  unknown.  Clinically,  toxicity 
presents with several syndromes. The most common of these is the development of a 
symptom  complex  characterized  by  fever,  dyspnea,  cough,  malaise,  and  myalgias, 
usually within weeks after initiation of therapy. Chest radiograph usually shows diffuse 
interstitial  infiltrates.  Occasionally, chest radiograph may show unilateral or bilateral 
effusions,  a  nodular  appearance,  or  may  even  be  normal.  Additionally,  hilar  and 
mediastinal adenopathy have been observed. Skin rash is present in up to 17 percent of 
patients  and  peripheral  blood  eosinophilia  in  up  to  40  percent  of  patients. 
Bronchoalveolar lavage in this setting may show a lymphocytic alveolitis, suggestive of 
a hypersensitivity reaction. However, illness may resolve even with continuation of the 
drug, and rechallenge does not necessarily result in relapse. These findings suggest that 
hypersensitivity  may  not  be  the  true  mechanism  of  injury.  This  presentation  of 
methotrexate-induced pulmonary toxicity parallels the hypersensitivity-type syndrome 
that is sometimes observed with bleomycin. As some patients may go on to develop 
chronic  pneumonitis  and  pulmonary  fibrosis,  the  drug is  generally  withdrawn when 
toxicity  occurs.  Pulmonary  toxicity  from methotrexate  may  also  present  as  a  more 
insidious sub acute syndrome of interstitial lung disease. Symptoms including cough, 
fever,  dyspnea,  headache,  and  malaise  typically  occur  within  4  months  after  the 
initiation  of  treatment.  Radio  graphically  and  clinically  this  syndrome more  closely 
resembles the type of chronic pneumonitis seen with other cytotoxic drugs and has been 
described as complicating all routes of Methotrexate administration (oral, intravenous, 
intrathecal). In contrast to many other chemotherapeutic agents, the pneumonitis caused 
by methotrexate  appears  in  general  to  be  responsive  to  corticosteroids.  Pathological 
findings in the lung parallel those seen with lung injury due to other cytotoxic drugs, 
with  interstitial  and  alveolar  inflammation  and  fibrosis.  Additionally,  eosinophilic 
infiltration of the interstitium as well as granulomatous inflammation may be observed. 
These latter findings are again suggestive of a potential hypersensitivity-type mechanism 
of  inflammation.  Methotrexate-induced  lung  injury  may  also  appear  as  an  acute 
syndrome  with  pleuritis  and  pleural  effusion.  Respiratory  distress  progressing  to 
noncardiogenic pulmonary edema has been described 
nafter intrathecal administration of the drug and may be neurogenic in origin18. 
In  patients  with  rheumatoid  arthritis,  polymyositis,and  other  collagen  vascular 
diseases,  the  potential  for  a  variety  of  pulmonary  manifestations  related  to  the 
underlying  disease  can  make  the  diagnosis  of  methotrexate-induced  pneumonitis 
challenging. The diagnostic criteria of Searles andMckendry are frequently employed in 
an  effort  to  determine  whether  pulmonary  involvement  is  related  to  methotrexate. 
Though  they  have  not  been  validated  in  a  prospective  cohort,  these  criteria  are 
commonly  used  to  assist  with  this  diagnosis.  In  a  multicenter  case-control  study  of 
methotrexate-induced lung toxicity in patients with rheumatoid arthritis,  Alarcon and 
colleagues  identified  risk  factors  associated  with  the  development  of  pneumonitis, 
including  age  greater  than  60  years  (associated  with  a  six  fold  increase  in  risk  of 
pneumonitis compared with those less than 50 years of age), prior history of rheumatoid 
pleuro-pulmonary  disease,  diabetes,  previous  use  of  disease-modifying antirheumatic 
drugs, and hypoalbuminemia. The prognosis with methotrexate associated lung toxicity 
is generally felt to be favourable. As noted, symptoms and radiographic abnormalities 
may resolve even with continuation of treatment. The use of corticosteroids is generally 
recommended though prospective trials of this intervention are not available. The overall 
mortality rate with methotrexate induced pneumonitis is approximately 10 percent.
m
SEARLES AND MCKENDRY CRITERIA19:
Diagnostic criteria:
Acute onset of breathlessness.
Fever (>38 C).
Tachypnoea (> or = 28 breaths / minute) with non productive cough.
Radiographic infiltrates of interstitial or alveolar infiltrates.
WBCs < or =15,000.
Negative blood or sputum culture for pathogenic organisms.
Pulmonary function tests showing restrictive pattern with low diffusion 
capacity.
PaO2 < 55mmhg in room air.
Biopsy,  histopathology  consistent  with  bronchiolitis  or  interstitial  pneumonitis  with 
giant cells and without evidence of pathogenic organism.
Presence of Methotrexate pneumonitis:
Definite : at least 6
Probable :at least 5
Possible : at least 4
MODIFIED SEARLES AND MCKENDRY CRITERIA:
MAJOR CRITERIA:
1.  Hypersensitivity  pneumonitis  by  histopathology  without  evidence  of  pathogenic 
organism.
2. Radiological evidence of pulmonary interstitial or alveolar infiltrates.
3. Blood cultures (if febrile) and initial sputum cultures (if sputum is produced) negative 
for pathogenic organisms.
MINOR CRITERIA:
1. Shortness of breath < 8 weeks.
2. Non productive cough
3. O2 saturation < 90% at the time of initial evaluation on room air.
4. DLco < or = 70% predicted for the age.
5.leukocyte count < or = 15000/mm3.
A definite case had to meet major criterion 1 (pathologic evidence) or criteria 2 
(radiologic  evidence  or  an abnormal  chest  radiograph)  and 3(negative  cultures)  plus 
three of the five minor criteria (shortness of breath, non productive cough, O2 saturation 
≤  90%,  DLCO  [diffusing  capacity  of  the  lung  for  carbon  monoxide]  ≤  70%,  and 
leukocyte count ≤ 15 000 cells/mm3). Patients were said to have met major criterion 3 if 
they were afebrile and did not produce sputum, even if no blood or 
sputum cultures were done. In some patients, bronchoalveolar lavage fluid was 
cultured to rule  out  infectious causes of  disease.  Probable case-patients  had to  meet 
major criteria 2 and 3 plus two of the five minor criteria. No other case-patients were 
considered to have methotrexate-induced lung injury.
PSORIASIS AND METHOTREXATE
Pulmonary disease in the course of psoriasis is rare. Possible aetiologies include 
microbial infection, a drug-induced reaction and capillary leak syndrome20. An 
infectious origin for the pulmonary involvement in patients seems improbable because 
of the absence of micro organisms in the repeated blood samples and alveolar lavage. 
The absence of improvement under broad-spectrum antibiotics and the rapid 
improvement with corticosteroids also make this aetiology unlikely. The hypothesis of a 
drug-induced reaction is plausible. Methotrexate and acitretin, two drugs frequently used 
in psoriasis, may both be responsible for interstitial pneumonitis, along with gold salts 
classically used in the treatment of psoriatic arthritis. Low-dose methotrexate is 
responsible for immunoallergic interstitial pneumonitis in up to 3% of patients treated 
for rheumatoid arthritis21-22. This complication is less frequent in patients treated for 
psoriasis than for rheumatoid arthritis, perhaps because the latter predisposes the lungs 
to drug-induced damage22-26. The pathogenesis of psoriasis-associated aseptic 
pneumonitis is 
unknown27. However, it has recently been shown in an animal model that T-helper (Th) 
1 lymphocytes, which are known to be activated in psoriasis, could induce 
alveolitis28 and that tumour necrosis factor, a major Th1 cytokine produced in 
psoriasis29, could promote lung invasion by lymphocytes by up regulating cytokines 
involved in cell adhesion30. Although methotrexate pneumonitis is not considered a 
dose-related phenomenon, the incidence of this adverse effect during low dose and long 
term methotrexate therapy needs further Investigations. Five clinical pulmonary 
syndromes have been associated with methotrexate treatment. Non-cardiogenic 
pulmonary edema and pleuritis are uncommon and have been reported in patients 
receiving methotrexate for malignancies at high doses. Pulmonary nodulosis has been 
described in a rheumatoid arthritis patient. Acute interstitial pneumonitis is the most 
common pulmonary toxicity and is characterized by shortness of breath, non-productive 
cough, fever and fatigue with radiographic bilateral interstitial and/or alveolar infiltrates. 
Interstitial fibrosis has been reported in patients receiving methotrexate for rheumatic 
and non-rheumatic conditions. Some of them, such as psoriasis, are not associated with 
the development of interstitial pulmonary fibrosis as part of the underlying disease 
process. In a recent case-control study the strongest risk factors for lung injury identified 
in patients with rheumatoid arthritis (RA) receiving methotrexate were older age, 
rheumatoid pleuropulmonary disease, previous use of disease-modifying antirheumatic 
drugs, low serum albumin, and the presence of diabetes.
dDIFFUSION:
By the time inspired gas reaches the alveoli, movement of gas molecules Is determined 
almost entirely by diffusion; This is so efficient that alveolar gas can be considered 
uniform without the existence of any intra-alveolar gas concentration gradients. Gas 
transfer across the alveolar wall into the pulmonary capillary involves passage of 
molecules through the epithelial cell, basement membranes, the interstitium and the 
endothelial cell and thence through plasma and the red cell membrane to the interior of 
the red cell. The rate of gas transfer in the lung depends on:
1surface area available for transfer;
2 thickness of the alveolar–capillary membrane;
3 solubility and molecular weight of the gas concerned
CO2 has a similar molecular weight to O2 but diffuses about 20 times more rapidly 
because of its high solubility. The diffusing capacity (DL) for a gas within the lung can 
be expressed by the following equation:
                        DL = VGAS/P1 – P2    ………………(1)
 
where Vgas is the volume of gas transferred in unit time and P1 and P2 are the pressures 
of gas in alveoli and capillary blood respectively. Thus the diffusing capacity for carbon 
monoxide (CO) is defined as:
                      DLCO = VCO/ P1 – P2     ………………(2)
and since the PCO in capillary blood is usually so small that it can be neglected, Eqn 2 
can be simplified to: 
                   DLCO = VCO/PAco           …………………(3) 
It is now agreed that the normal alveolar membrane causes no appreciable impediment 
to O2 diffusion from alveoli to blood. Theoretically, diffusion may be influenced by 
intra-alveolar oedema or exudate, interstitial oedema, exudate or fibrosis, thickening of 
the alveolar wall, thickening of the capillary membrane or increase of the intracapillary 
path for O2 due to capillary dilatation. Pulmonary diffusing capacity measures the 
impediment produced by all the factors involved in transfer of O2 to the erythrocyte; for 
the whole lung the VA/Q ratio is probably the most important factor. In high VA/Q areas, 
ventilation is wasted and little or no gas is exchanged in spite of an intact transfer 
surface leading to a decrease in DLCO for the lungs as a whole. There are no methods at 
present available that can distinguish between VA/Q abnormality and impaired diffusion 
but the general consensus of opinion 
is that VA/Q disturbances are more important than thickening of the alveolar membrane. 
A significant part of the diffusion pathway lies between the capillary endothelium and 
the red cell. An additional factor that influences diffusion of  O2 is the rate of the 
chemical reaction that combines O2 with haemoglobin within the red cell. The diffusing 
capacity can thus be considered as having two components, the first reflecting transfer 
from the alveolus to the interior of the red cell and the second concerned with the 
combination of O2 with haemoglobin. These two components can be expressed as the 
inverse of their effective diffusing capacities in the following equation:
1/DL =1/Dm +1/QVc         …………………….(4)
where Dm is the membrane component of resistance to diffusion, Q describes the rate of 
reaction of O2 with haemoglobin and Vc is the volume of capillary blood. QVc is thus 
the effective diffusion capacity for the rate of reaction of O2 with haemoglobin. These 
two separate components of the resistance to diffusion can be measured by special 
methods and are approximately equal. Significance of changes in DLCO From Eqn 4 it 
follows that changes in capillary blood volume can influence DL, which in consequence 
is decreased in anaemia and 
increased in polycythemia, left-to-right cardiac shunts, exercise and the supine position. 
A low value for DL may also indicate:
1 small lungs or lesions reducing lung volumes, e.g. pneumonectomy;
2 obstructive lung disease with non-uniform VA/Q distribution;
3 emphysema with decrease of total gas-exchanging area;
4 interstitial lung disease with altered ventilation, perfusion and probably diffusion in 
many areas.
DL is of particular value in defining abnormality and response to treatment in the 
interstitial lung diseases, which include fibrosing alveolitis, sarcoidosis, asbestosis, 
farmer’s lung, collagen diseases of the lung and polyarteritis nodosa. In some 
conditions, e.g. sarcoidosis, changes in DL may be a more sensitive indicator of 
response to treatment than radiological changes. DL has also been used (after adjustment 
for the ventilated lung volume to give the KCO) as a measure of fresh pulmonary 
haemorrhage in Goodpasture’s syndrome, where increases in KCO are attributed to 
uptake of CO by sequestered haemoglobin in the lung. Ideally, the gas used for 
estimations of DL should be O2, and the relevant equation is: 
DLO2 =VO2/PAO2 – PC02       ..........................(5)
where  PcO2 is mean pulmonary capillary pressure. Such measurements are possible 
although because of the difficulty in measuring PcO2 it is more usual in routine practice 
to measure DLCO. CO has a great affinity for haemoglobin (240 times that of O2). At 
low alveolar pressures of CO only a small proportion of haemoglobin is saturated with 
CO during passage through the pulmonary capillaries, so that the PCO in the blood is 
small relative to the PCO in the alveoli. The relatively large difference between PACO 
and  PcCO makes the CO method for measuring diffusion capacity more accurate and 
reproducible  than  the  O2  method.  In  essence  the  techniques  employed  require 
measurement of the uptake of CO (VCO) and PACO by means of an infrared analyser, 
PcCO is  assumed  to  be  zero  and  the  values  are  entered  into  Eqn  3.  Simultaneous 
measurement of alveolar volume by He dilution also allows determination of the transfer 
coefficient  (DLCO/VA, or  KCO), which may be a more appropriate indicator  of the 
effectiveness of gas exchange when lung volume has been lost because of either disease 
or surgery. Although steady-state measurements of  DLCO are possible,  they are less 
reproducible than the single-breath method that is currently the procedure of choice.
COLLINS AUTOMATED SYSTEM FOR 
MEASURING DLCO
ATS RECOMMENDATION FOR PERFORMING DLCO:
Equipment:
1. Volume accuracy same as for spirometry(±3% over 8L range, all gases)
2. Documented analyzer linearity from 0 to full span ± 1%
3. Circuit resistance less than 1.5cm H2 O at 6 L/sec flow
4. Demand valve sensitivity less than 10 cm H2O to generate 6L/sec flow
5. Timing mechanism accurate to ±1% over 10 sec; checked quarterly
6. Documented instrument dead space(Inspiratory/Expiratory) less than 0.1L
7. Check for leaks and volume accuracy(3L calibration) daily
8. Validate system by testing healthy non smokers ( Biologic control ) quarterly
Technique:
1. Subject should refrain from smoking for 24 hours before the test
2. Subject should be instructed carefully before the procedure
3. Subject should inspire rapidly;2.5 sec or less for healthy subjects, 4 sec or less in 
obstruction
4. Subject should achieve an inspired volume greater than 90% of VC
5. Subject should achieve breath hold for 9-11 sec, relaxing against closed glottis or 
closed valve ( No valsalva or mullers manoeuvre )
6. VD  wash out should be 0.75 L-1.0L(0.5 L if VC less than 2.0 L)
7. Alveolar sample volume should be 0.5-1.0 L collected in less than 4 sec
8. Visual  inspection  of   VD   washout  and  alveolar  sampling  should  be  used  for 
system that continuously analyzes expired gas
9. Test  gas  should  contain  21%  O2 at  sea  level;  supplemented  O2 should  be 
discontinued before testing if possible
10. Four minutes should elapse between repeat tests
Calculations:
1. Average at least two acceptable tests; duplicate determinations should be within 
10% or 3ml/min/mm of Hg 
2. Use Jones method of timing of breath hold
3. Alveolar volume should be determined by single breath dilution of tracer gas
4. Adjust for VD volumes (Instrument and patient )
5. Determine  inspired gas conditions( ATPS or ATPD )
6. Correct for CO2 and H2O absorption
7. Report DL/VA in ml CO ( STPD )/min/mm Hg per L( BTPS )
8. Correct for Haemoglobin concentration
9. Adjust for COHb
10. Adjust for altitude
11. Use  reference  equations  appropriate  to  the  laboratory  method  and  patient 
population
Acceptable test criteria for diffusing capacity of the lung for carbon monoxide:
Use of proper quality-controlled equipment,  VI   (Inspired Volume) of  >85% of 
largest VC in  <4 sec, A stable calculated breath hold for 10±2 s. There should be no 
evidence of leaks, or Valsalva or Mueller maneuvers, Expiration in  <4 s (and sample 
collection time <3 s), with appropriate clearance of VD (Dead space volume) and proper 
sampling/analysis of alveolar gas. 
Pulmonary Function Tests in DPLD
1.Severity and pattern of disease
Simple lung function testing using lung volumes and gas transfer factor gives a 
reasonable measure of the extent of disease.
2. Monitoring the course of the disease
VC and DLCO are the most  appropriate and simplest  indicators  of  change in 
DPLD.  DLCO   predict  survival  in  some  studies.  In  Wells  et  al20 study,  increased 
mortality is associated with reduced DLCO, FVC and TLC. The one index that appears 
to be a good predictor of the subsequent clinical course is DLCO.  
RADIOLOGIC IMAGING IN DPLD
Patients with suspected DPLD will have a chest radiograph as the initial imaging 
investigation.  In  most  cases,  this  is  abnormal  and  occasionally  the  radiographic 
appearances are  sufficiently  characteristic  to  enable  a  specific  diagnosis  to  be made 
when taken in conjunction with the clinical and laboratory findings. Chest radiograph  is 
an  essential  test  for  the  assessment  of  DPLD,  however  a  normal  Chest  Radiograph 
cannot exclude the diagnosis. If available, previous x-rays or reports of x-rays should be 
obtained and compared with the recent x-rays. In appropriate clinical settings, HRCT 
may be sufficiently characteristic to preclude the need for biopsy7.
PULMONARY HRCT
HRCT scanning is capable of imaging the lung with excellent spatial resolution 
and providing anatomical detail similar to that seen by gross pathological examination. 
Images  are  usually  obtained  in  the  supine  and  prone  position.  In  normal  patients, 
dependent lung opacity is often seen in the posterior, subpleural regions of the lung. In 
certain diffuse lung diseases, such as non specific interstitial pneumonia (NSIP), images 
can be identical to those seen in normal patients. Prone images will differentiate between 
these  two  possibilities,  since  normal  dependent  density  in  the  posterior  lung  will 
disappear  on  prone  images,  whereas  true  lung  disease-related  density  will  persist. 
Dynamic expiratory images are also obtained to screen for air trapping.
1. Detection of DPLD
HRCT scanning is able to detect DPLD not visible on the chest radiograph. The 
relative sensitivities of the two techniques for the detection of DPLD are 94% and 80%, 
respectively.             
2. Characterisation of disease and extent of disease  
 The diagnostic accuracy of HRCT scanning is  further  increased by concurrent 
clinical  evaluation49.Unlike  chest  radiography,  HRCT  scans  provide  cross  sectional 
images and the extent of disease is therefore much more readily appreciated than on the 
chest  radiograph.  HRCT  scanning  may  also  elucidate  patients  with  complex  lung 
function abnormalities—for example, co-existing fibrosing  alveolitis and emphysema.   
3. Impact on lung biopsy samples  
HRCT scanning has a high degree of accuracy in many forms of DPLD. The 
percentage of first choice diagnoses made with a high level of confidence in two studies 
was  82% and 93%.Fibrosing  alveolitis  may  be  confidently  distinguished from other 
forms  of  DPLD with  an  accuracy  of  88%.  Using  Bayesian  analysis,  Grenier  et  al  
concluded that the combination of clinical, radiographic, and HRCT findings enabled a 
correct diagnosis with a high level of confidence in 61–80% of patients with DPLD. 
Based on the findings it  is  evident  that  HRCT scanning can prevent  the need for  a 
histological diagnosis.   For patients in whom lung biopsy samples are required, HRCT 
scanning is better able to differentiate between the need for transbronchial biopsy or 
open lung biopsy samples. It is also able to determine the most appropriate areas from 
which the biopsy samples should be taken.
4. Assessment of disease activity 
There is evidence that a predominant ground glass pattern and is more likely to 
represent active inflammatory disease and to respond to appropriate therapy  Reticular 
and honeycomb patterns on HRCT scans correlate well with histological evidence of 
fibrosis.   
5. Prediction of response to treatment 
Because of its ability to differentiate between cellular and fibrotic disease with 
reasonable accuracy, HRCT scanning can be used to predict response to treatment and is 
significantly more accurate than chest radiography in this respect. 
HRCT PATTERNS
1. Reticular opacities: Thickening of the interstitial connective tissue network of the 
lung will result in reticular opacities of varying morphology. This thickening can 
result from fluid/cellular infiltration or deposition of fibrous tissue.
2. Nodules:  There  are  several  ways  to  classify  nodules:  well  defined  vs.  poorly 
defined;  upper  vs.  lower  lobe  distribution;  and  relationship  to  the  secondary 
pulmonary lobule. The last is the most useful characteristic, since it provides a 
focused  differential  diagnosis  and  is  reflective  of  the  underlying  disease 
pathophysiology.  There  are  three  possible  HRCT  distributions  of  nodules: 
perilymphatic, random, and centrilobular.
3. Honeycombing: Honeycomb lung remodelling (honeycombing) reflects the end 
stage of a number of diseases that cause parenchymal destruction. It presents a 
characteristic HRCT pattern, with subpleural, thick-walled cysts that share walls 
and, when advanced, are often stacked in multiple layers. Other signs of fibrosis 
(traction bronchiectasis and reticulation) typically accompany it. Honeycombing 
is  highly  suggestive  of  a  pathologic  diagnosis  of  usual  interstitial  pneumonia 
(UIP), although it can be attributable to other diseases
4. Traction  bronchiectasis:  Bronchial  dilatation  occurring  as  a  consequence  of 
interstitial  fibrosis  is  referred  to  as  traction  bronchiectasis.The  bronchi  often 
appear irregular (corkscrewed) and are not associated with radiologic evidence of 
bronchial inflammation (gross bronchial wall thickening or mucous impaction). 
Other  signs  of  lung  fibrosis  (honeycombing  or  irregular  reticulation)  often 
accompany traction bronchiectasis. While traction bronchiectasis is quite specific 
for fibrosis, the differential diagnosis is broader than that of honeycombing.  In 
patients  with  known  collagen  vascular disease,  bibasilar,  peripheral,  traction 
bronchiectasis  accompanied  by  ground-glass  attenuation  can  be  considered 
diagnostic of NSIP.
5. Ground glass opacity:GGO  is increased lung opacity that does not obscure the 
associated vessels and represents abnormalities below the resolution of HRCT. 
GGO has  been  associated  with  active  or  reversible  lung  disease.  However, 
ground-glass  opacity  can  also  be  seen  in  cases  in  which  fibrosis  is  the 
predominant  abnormality.  Ground-glass  attenuation  can  only  be  considered  as 
reflecting the presence of potentially reversible disease if there are no associated 
findings of fibrosis in the same area. The differential diagnosis of ground glass 
opacity should be based upon the host immune status and duration of symptoms. 
The presence of connective tissue diseases, environmental inhalants, and drug use 
also should be considered when increased diffuse lung opacity is present.
Pulmonary Function Tests
Full pulmonary function tests (PFT) should be performed in all cases of suspected 
DPLD. They aid in the diagnosis, assessment of disease severity, response to treatment 
and prognosis. PFT measurements should include forced expiratory volume in 1 second 
(FEV1), forced vital capacity (FVC), FEV1/FVC ratio, vital capacity (VC) and diffusion 
capacity of carbon monoxide.
Lung  function  tests  are  usually  restrictive  with  small  lung  volumes  seen  as 
reduced VC in DPLD. The FEV1/FVC ratio is  either  maintained or  often increased. 
DLCO  is  typically  reduced  in  DPLD  to  greater  extent  than  the  lung  volumes. 
Coexistence of DPLD with obstructive airway disease (e.g. emphysema), can confuse 
the results with a mixed pattern of restriction observed as reduced lung volumes and 
obstruction manifesting as a reduced FEV1/FVC ratio. DPLD are usually thought to be 
characterised by restrictive lung function, by which is meant a reduction in lung volumes 
with preserved ratio of forced expiratory volume in one second.
Diagnosis and assessment of diffuse parenchymal lung disease can be done with 
FEV1, forced vital capacity (FVC), FEV1/FVC ratio, and  VC   together  with a reduction 
in  carbon monoxide  transfer  factor (DLCO). However, in early disease lung volumes 
and  transfer  factor  may  be  within  the  normal  range.  Lung  function  tests  are 
conventionally  used  to  give  a  global  index of  functional  impairment.  Vital  capacity 
(VC), total lung capacity (TLC), and DLCO are most commonly used while in the UK, 
exercise testing is used relatively little. Several studies have correlated lung function and 
exercise  test  parameters  with the degree of pathological  abnormality  on lung biopsy 
samples  using  the  latter  as  the  gold  standard.  Watters  et  al  developed  a  composite 
clinical radiographic physiological (CRP) score using seven variables: dyspnoea, chest 
radiograph, FEV1 and FVC, TLC, DLCO/VA, resting A–a gradient, and exercise oxygen 
saturation.
XRAY CHEST PA VIEW of a patient with methotrexate induced pulmonary 
toxicity.
HRCT CHEST of the same patient whose x-ray is given above
HRCT CHEST of another patient with traction bronchiectasis
MATERIALS AND METHODS
POPULATION STUDIED
This is a cross sectional study done by Institute of Thoracic Medicine, Chetpet 
and  Government  general  hospital,  Chennai  during  the  period  from  march  2009  to 
september2009.The study patients were from Department of Dermatology, Government 
General Hospital , Chennai.
INCLUSION CRITERIA:
1.   Psoriasis  patients  have  taken  more  than  3  months  of  methotrexate  with 
respiratory complaints.
2. Age group above 14 years
3. Patients who were willing for the study and gave informed consent for the 
study.
           4. Both sexes
EXCLUSION CRITERIA:
Not able to perform PFT
Patients treated for pulmonary tuberculosis in the past
Patients known to have restrictive lung diseases due to other known causes like 
collagen vascular diseases.
METHOD :
All eligible Psoriasis patients who are on methotrexate therapy for more than 3 
months (cumulative dosage exceeding 150mg) were subjected to detailed history taking, 
clinical  examination,  complete  haemogram,  liver  function  test,  renal  function  test, 
spirometry,  diffusion  capacity  of  carbon  monoxide  and  radiological  examination 
including x-ray chest and HRCT Chest ( read by 2 independent readers).The data were 
tabulated and analysed.
ATS RECOMMENDATION FOR PERFORMING SPIROMETRY
Procedures for recording spirometry were done as per ATS recommendation that 
include;  Checking  the  spirometer  calibration,  Explanation  of  the  test  to  subject, 
Preparation of the subject including asking about smoking, recent illness, medication use 
and  measurement  of  weight  and  height.  The  subject  were  then  instructed  and 
demonstrated about the test including correct posture with head slightly elevated, rapid 
and complete inhalation and exhalation with maximal force.
After assuming the correct posture nose clip was attached and mouthpiece was 
placed in mouth with close lips around the mouthpiece. Patient was instructed to inhale 
completely and rapidly with a pause of one second at Total Lung Capacity and then to 
exhale  maximally  until  no  more  air  can  be  expelled  while  maintaining  an  upright 
posture.  Repeated  instructions  were  given.  Minimum  of  three  manoeuvres  were 
repeated; no more than eight are usually required. 
The  variables  recorded  included  FVC,  FEV1  and  FEV1 /FVC  ratio.  Three 
technically satisfactory measurements were obtained in which FVC was reproducible 
within  300  ml.  The  subject’s  FVC  was  defined  as  the  maximal  FVC  which  was 
determined before the DLCO test, as recommended by the ATS.
ATS RECOMMENDATION FOR PERFORMING DLCO
DLCO measurements were performed in compliance with the American Thoracic 
Society (ATS) guidelines. DLCO was measured using a single-breath technique. The 
DLCO was routinely  adjusted  for  haemoglobin  if  the  value  was  outside  the normal 
range. Measurements of DLCO were made with a Collins automated system using a gas 
mixture that contained 0.3% Methane tracer gas and 0.3% carbon monoxide. The breath 
holding time was 10 seconds and the washout volume was 0.75 L. Each subject’s height 
and weight were measured. 
The  participants  were  seated,  wearing  nose  clips,  and  performed  at  least  two 
DLCO manoeuvers separated by more than 4 minutes.  The mean DLCO value from two 
manoeuvers that matched within 3 ml/min/mm Hg was reported. 
Before  the  test  was  performed,  each  subject  was  instructed  about  all  of  the 
required  manoeuvers.  After  the  subject  had  adapted  to  the  mouthpiece  of  the  test 
apparatus, four or five tidal volumes were recorded to determine a regular end expiratory 
baseline.  The  subject  was  then  asked  to  exhale  as  far  as  possible,  to  the  point  till 
maximal exhalation had been reached (residual volume RV); making a rapid, maximal 
inhalation within 2 to 2.5 seconds to VC continuing to hold the breath for 10 seconds 
while relaxing against  a closed glottis  and exhaling rapidly. If after two attempts an 
acceptable measurement could not be made, the procedure was then abandoned.
The values were interpreted as follows: 
DLCO and DLCOHb : Normal(>80% predicted)  Mild diffusion defect (65-80%), 
Moderate diffusion defect(45-65%) and severe diffusion defect(<45%).         
FVC:Normal(>80%  predicted),  Mild  Reduction(60-80%),  Moderate 
Reduction(40-60%), Severe Reduction(<40%).
RESULTS
In this study 154 patients from the outpatient department of psoriasis clinic of 
dermatology department of government general hospital, Chennai who were receiving 
methotrexate for psoriasis were screened. Out of which 30 patients who were eligible as 
per inclusion criteria were included in the study. Out Of these patients 7 were smokers, 2 
were diabetic,2 were hypertensive out of which 1 was known patient of rheumatic heart 
disease  on  treatment  and  4  were  known  bronchial  asthma  patients.  None  of  these 
patients with co-morbidity had methotrexate induced fibrosis. 
AGE AND SEX DISTRIBUTION:
AGE AND SEX DISTRIBUTION
In this study, there were 15 males and 15 females.
Their age distribution was:
20-35 years 35-50 years 51 to 65 years >65 years
males 2 5 6 2
females 4 9 2 0
COMORBID CONDITIONS: 
  
RADIOLOGICAL LESION VS PFT:
RADIOLOGICAL LESION VS SPIROMETRY:










10 3 5 9 27
Total 13 3 5 9 30
There were 21 patients with spirometric abnormalities.3 patients with radiological 
lesions had restrictive pulmonary function defect.10 patients without radiological lesions 
had restrictive pulmonary function defect.3 patients had obstruction.5 patients had early 
obstruction as  suggested by decrease in mid mean expiratory flow,  normal  fev1 and 
normal chest x-ray. 
There  were  11  (36.6%)  patients  with  restrictive  ventilatory  defect  without 
radiological  abnormalities,  7  (23.3%)  patients  with  diffusion  defects  without 
radiological abnormalities. There were 5 (16.6%) of patients with small airway disease 
as evidenced by decrease in mean mid expiratory flow without other ventilatory defects 
and normal x-ray chest.
There were 3 patients with restrictive ventilatory defect and no diffusion defect 
and 2 patients with diffusion defect and no restrictive ventilatory defect. 2 patients had 
diffusion  defect,  small  airway  disease  (decreased  mmef)  radiological  lesions  but  no 
restrictive ventilatory defect.
CUMULATIVE DOSE VS PFT:
Diffusion defect and restrictive ventilatory defect occurred with least cumulative 
dose  of  150mgs.  Small  airway  disease  occurred  with  a  least  cumulative  dose  of 
860mgs.Least cumulative dose at which methotrexate induced pulmonary toxicity (10%) 
occurred was 2250 mgs.3 (10%) patients had received above this cut off cumulative 
dose without developing radiological lesions or pulmonary function defects. Hence in 
this study pulmonary toxicity seems to be independent of cumulative dose and is not 
dose dependant
CUMULATIVE DOSE AND PULMONARY FUNCTION
EOSINOPHILS VS PFT:
Ventilatory 
defects restriction Diffusion defect
early 
obstruction normalEosinophils%
< 7% 9 8 2 8
>7% 4 2 3 3
Total 13 10 5 11




restriction obstruction Early obstruction
Total 
(no:21)
Symptoms  >  1 
month
       
        4        2
       
       2         8
Symptoms <1 
month
        
        9        1
       
       3         13
Total 
        
       13        3
      
       5         21
All 3 patients with pulmonary fibrosis presented with respiratory symptoms more 
than  1  month.  There  were  5  patients  with  symptoms,  no  pulmonary  fibrosis  and 
diffusion defect. There were 2 patients without symptoms, no pulmonary fibrosis and 
diffusion  defect.  There  were  2  patients  with  symptoms,  restrictive  pattern  and  no 
pulmonary fibrosis. There were 8 patients without symptoms, restrictive pattern and no 
pulmonary  fibrosis.  There  were  2  patients  with symptoms,  early  obstruction  and no 
pulmonary fibrosis. There were 3 patients without symptoms, early obstruction and no 
pulmonary fibrosis. 
SYMPTOMS VS DIFFUSION DEFECT:
Diffusion defect Normal diffusion Total
Symptoms > 1 month
           5            3          8
Symptoms < 1month
           5           17          22
Total           10            20          30
PSORIATIC ARTHRITIS AND PULMONARY IMPAIRMENT:
There were 5 patients with psoriatic arthritis in this study.1 patient had pulmonary 
fibrosis.2  patients  had  diffusion  defect  and  2  patients  had  restrictive  pattern  in 
spirometry.  
METHOTREXATE INDUCED PULMONARY FIBROSIS:    
There were 3(10%) cases of methotrexate induced pulmonary toxicity according 
to modified searles and mckendry criteria. All of them (100%) had pulmonary diffusion 
defects.2  (66%)  had  restrictive  ventilatory  defects  only.  There  were  2  males  and  1 
female patient. 2 males were above 50 years with psoriasis vulgaris and female was 20 
years with pustular psoriasis. All 3 patients had dry cough and dyspnoea for more than 1 
month.  2 patients (66%) had bilateral  diffuse interstitial  fibrosis.  1(33%) patient had 
bilateral lower lobe traction bronchiectasis.
Patient 1 Patient 2 Patient3
Age 60 20 56
Sex male Female Male
Psoriasis type Psoriasis vulgaris Pustular psoriasis Psoriasis vulgaris
Fever no no No
cough yes yes No
Expectoration No no No
Dyspnoea yes yes Yes
Duration  of 
symptoms
4 months 4 months 4 months
Total count 8000/cmm 14600/cmm 7600/cmm
Eosinophils 2% 4% 2%
X-ray chest B/L Interstitial 
pattern
B/L lower zone 
reticular shadows
B/L Interstitial pattern
HRCT Chest B/L Interstitial 
fibrosis




PFT Severe restriction Moderate restriction Normal
Diffusion capacity Severe Mild Mild
Arthritis No No Yes
Cumulative dose 9360 8340 2250
Dose / week 30mg 15mg 7.5mg
DISCUSSION
In this study 9 patients showed normal radiology and pulmonary function test.21 
patients had pulmonary function abnormalities.
In this study there were 13 (43%) patients with restrictive pulmonary function 
defect.  Belzenegui et al reported 2 cases with mild restriction among 27 patients in a 
similar study . 
There were 10 (33%) patients with diffusion defect in this study. Belzenegui et al 
reported 2 cases among 27 patients in a similar study.
There were 5 (16%) patients with small airway disease as suggested by decrease 
in mean mid expiratory flow. Belzenegui et al reported 5 cases among 27 patients in a 
similar study. 
There were 3 (3%) patients with radiological lesions, 1 had bronchiectasis and 2 
had interstitial fibrosis.
Patients  with  Co-morbidities  like  bronchial  asthma  (n=3),  rheumatic  heart 
diseases (n=1), hypertension (n=1),diabetes mellitus (n=1) and habits like smoking(n=7) 
did not have radiological features of methotrexate induced pulmonary fibrosis.
There was no case of acute pneumonitis during the study period. 
Average duration of respiratory symptoms in suspected patients was more than 1 
month.
The  study  is  comparable  with  the  previous  studies  with  prevalence  rate  for 
methotrexate  induced  pulmonary  fibrosis  nearing  2%  of  154  patients  receiving 
methotrexate from dermatology outpatient department.Diffusion capacity was an useful 
aid in all 3 patients with methotrexate induced pulmonary toxicity. 
CONCLUSIONS
There were 3 (10%) patients with radiological evidence of methotrexate induced 
pulmonary fibrosis.
There were 10 (33%) patients with restrictive pulmonary function defect without 
radiological evidence of methotrexate induced pulmonary fibrosis.
There  were  7  (23%)  patients  with  diffusion  defect  in  this  study  without 
radiological evidence of methotrexate induced pulmonary fibrosis. Of these 7 patients, 5 
patients had spirometric defect in the form of restriction.
There were 14 (47%) patients with symptoms, no radiological abnormality and no 
spirometric abnormalities.  Of the above 14 patients,  2 patients (6.6%) had  diffusion 
defect.
Prevalence  of  pulmonary  function  abnormalities  in  this  study  matches  similar 
studies elsewhere.
DLco could be an early predictor of pulmonary function impairment in psoriasis 
Patients on long term methotrexate. 
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ABBREVIATIONS
ATS American Thoracic Society
CVD            Collagen Vascular Disease
DIP            Diffuse Interstitial Pneumonia
DLCO            Diffusing Capacity for Carbon Monoxide
DLCO/VA Diffusing capacity for carbon monoxide per unit of alveolar volume
DPLD Diffuse Parenchymal Lung Disease
FEV1 Forced expiratory volume in 1 second
FVC Forced vital capacity
GGO Ground Glass Opacity
H2O              Water
Hb Haemoglobin
HRCT            High Resolution Computerised Tomography
ILD Interstitial lung diseases
KCO Transfer coefficient of the lung (DLCO/VA)
LIP Lymphocytic Interstitial Pneumonitis
MCTD            Mixed Connective Tissue Disease 
NSIP Non-Specific Interstitial Pneumonitis
O2                         oxygen
PaO2              partial pressure of oxygen
pPFT Pulmonary Function Test 
Q                    perfusion
RA Rheumatoid Arthritis
Th1                 T helper cells 1
TLC                Total lung capacity
VA Alveolar Volume
VD Dead space volume
WBCs            white blood cells
WK                 Week
PATIENT PROFORMA
Name : Age/Sex : Address :






Other Significant H/o :
Smoker / Non Smoker :
Blood Investigation :
Bid Hb  TC DC        ESR    RBS UREA      CREATININE
Na+ K+ S.Bilirubin(T)   SGOT       SGPT       SAP Protein(T) Albumin
ECG
CXR HRCT
SPIROMETRY
DLCO

